The United Kingdom and the United States have announced a significant bilateral deal that will guarantee zero tariffs on UK pharmaceutical shipments going into the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to boost spending on drugs through the NHS. This commitment ensures that import taxes on these crucial products will be held at zero for a duration of three years.
This deal is in response to earlier warnings to significantly raise import taxes on branded drug products, with figures floated as high as 100%.
"This deal between the UK reinforces the international landscape for cutting-edge drugs and introduces much-needed balance to transatlantic medicine commerce," a release noted.
Commercial Significance
Medicines constitute one of the UK's biggest goods shipped to the US, which is by far the primary buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to the third quarter, the UK exported pharmaceutical products worth billions to the US. This value accounted for 17.4% of all goods exports in that span.
"This agreement secures work, boosts funding and paves the way for the UK to become a worldwide center for biotech and pharma," a government official remarked.
Specific British Pledges
The deal entails several notable changes from the UK:
- Higher Cost Ceiling: The UK will increase the price threshold at which it deems new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a goal to raise overall NHS spending on drugs from 0.3% of GDP to 0.6% over the next decade.
- Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Previously, refunds were more than twenty percent.
Industry Background
The deal follows a long-running tension between the sector and the ministers over spending levels and approval rates.
These tensions were heightened by claims that American consumers were charged several times more for the identical medicines than people in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or scrapped, while major expansions have been pledged toward US facilities.
A senior figure stated that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its total funding over the last ten years.
